Obtaining this CPT code is an initial step to achieving reimbursement for the use of MuReva Phototherapy’s Photobiomodulation Therapy Device when it becomes commercially available

Brecksville, Ohio (December 16, 2025) – MuReva Phototherapy, an emerging leader in the treatment of radiation- and chemotherapy-induced oral mucositis in cancer patients, today announced that the American Medical Association (AMA) CPT Editorial Panel has approved a Category III CPT code (1011T) applicable to the use of MuReva Phototherapy’s proprietary intraoral devices. These devices deliver photobiomodulation (PBM) therapy designed to reduce the severity of oral mucositis for cancer patients receiving radiation therapy, with or without concomitant chemotherapy. The new CPT code will be effective as of January 1, 2026.

CPT codes are used by physicians and healthcare providers to identify medical services and procedures when submitting claims to health insurers for reimbursement. Category III CPT codes are temporary codes assigned to new procedures associated with emerging technologies and services. The newly established Category III code is specific to the delivery of PBM therapy  to the oral cavity using MuReva Phototherapy’s intra-oral devices.

“Securing a Category III CPT code is an important milestone in establishing reimbursement and making the MuReva OM accessible to the patients who need it most,” said Vedang Kothari, Founder and President of MuReva Phototherapy. “We are encouraged that leading oncology societies stepped forward to support our application, which reinforces the growing recognition of intraoral photobiomodulation as an emerging therapy for patients receiving radiation and chemotherapy.”

Oral mucositis is one of the most common and debilitating complications of cancer therapy. The condition affects more than 450,000 patients annually and is associated with a wide range of cancer treatments. It is especially prevalent in patients receiving radiation therapy, with or without concomitant chemotherapy, for head and neck cancer.

For more information on oral mucositis, visit oralcancerfoundation.org/complications/mucositis.

About MuReva Phototherapy

MuReva Phototherapy is a privately held company which was spun off from Lumitex, a lighting solutions manufacturer, in 2018. The company is developing the MuReva OM^TM, an innovative photobiomodulation device designed for patients at risk of oral mucositis. In addition to private funding, the company has been awarded both Phase 1 and Phase 2 Small Business Innovation Research (SBIR) grants from the National Institute of Health (NIH) which have supported the development of the company’s technology. The company received Breakthrough Device Designation in 2019 and recently completed a prospective, randomized clinical trial (NCT03972527) studying the safety and clinical utility of the MuReva OM to reduce the severity of oral mucositis in adult patients with head and neck cancer. The results from this study were recently reported during the 2025 American Society for Radiation Oncology (ASTRO) Meeting.